Lava Therapeutics is led by Paul Parren, Ph.D., who serves as the President and Chief Executive Officer of the clinical-stage immuno-oncology enterprise. Bringing deep scientific expertise and extensive biopharmaceutical leadership experience in antibody engineering and drug development, he guides the company's overarching strategic vision and clinical advancement of bispecific antibody platforms designed to engage gamma-delta T cells for targeted cancer therapy.